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Abstract
Introduction/objectives Adherence to prescribed medication regimens is fundamental to the improvement and maintenance of
the health of patients with rheumatoid arthritis. It is therefore important that interventions are developed to address this important
health behavior issue. The aim of the present study was to design and evaluate a theory-based intervention to improve the
medication adherence (primary outcome) among rheumatoid arthritis patients.
Methods The study adopted a pre-registered randomized controlled trial design. Rheumatoid arthritis patients were recruited
from two University teaching hospitals in Qazvin, Iran from June 2018 to May 2019 and randomly assigned to either an
intervention group (n = 100) or a treatment-as-usual group (n = 100). The intervention group received a theory-based intervention
designed based on the theoretical underpinnings of the health action process approach (HAPA). More specifically, action
planning (making detailed plans to follow medication regimen), coping planning (constructing plans to overcome potential
obstacles that may arise in medication adherence), and self-monitoring (using a calendar to record medication adherence) of
the HAPA has been used for the treatment. The treatment-as-usual group received standard care.
Results Data analysis was conducted based on the principle of intention to treat. Using a linear mixed-effects model (adjusted for
age, sex, medication prescribed, and body mass index), the results showed improved medication adherence scores in the
intervention group (loss to follow-up = 16) compared to the treatment-as-usual group (loss to follow-up = 12) at the 3-month
(coefficient = 3.9; SE = 0.8) and 6-month (coefficient = 4.5; SE = 0.8) follow-up. Intervention effects on medication adherence
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scores were found to be mediated by some of the theory-based HAPA variables that guided the study.
Conclusion The results of the present study support the use of a theory-based intervention for improving medication adherence
among rheumatoid arthritis patients, a group at-risk of not adhering to medication regimens.
Trial registration (in Iranian Registry of Clinical Trials) irct.ir, IRCT20180108038271N1
Key Points
• Theoretical underpinnings of the health action process approach are useful to improve medication adherence for RA patients.
Keywords Health action process approach .Medicine adherence . Rheumatoid arthritis . Social cognition
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disorder
that affects synovial joints, resulting in severe disability and
morbidity [1]. With disease progression, RA can also present
with extra-articular manifestations such as rheumatoid nod-
ules, pulmonary involvement or vasculitis, and systemic co-
morbidities [2]. RA affects approximately 0.5 to 1% of the
population worldwide [3], with reported prevalence of
0.33% in Iran [4]. Further, RA has been ranked as the 42nd
highest contributor to global disability of 291 conditions stud-
ied, carrying a substantial burden for both the individual and
society more generally [5]. Although modern medicine has
advanced treatments for the effective management of RA,
the long-term medical, social, and economic consequences
are still underestimated [6].
Drug therapy for RA patients is especially important to
improve radiographic disease progression, physical function,
and quality of life [7–9]. Although the drug treatment for RA
patients is complex (e.g., measurement on adherence is diffi-
cult to establish and outcomes are dependent on a range of
variables), prior research has demonstrated an association be-
tween higher medication adherence and better clinical re-
sponse to therapies in RA patients [10, 11]. Thus, improving
medication adherence in RA patients may, in turn, help to
improve their health outcomes. Despite this, a recent meta-
analysis revealed that only 66% of all patients are actually
adherent to their RA treatment regimen [12]. Strategies to
enhance medication adherence among RA patients are there-
fore of value to help maximize the efficacy of treatment and
minimize the course of RA progression.
Many researchers and clinicians have observed the prob-
lem of medication nonadherence among RA patients.
Consequently, programs for improving medication adherence
have been developed and studied [13–16]. However, the com-
monly used method of patient education in improving media-
tion adherence is questionable due to the reported limited
short-term benefits and inconsistent effects [17]. This suggests
that the use of education to improve medication adherence for
patients with RA, although perhaps important, is not sufficient
to change behavior to adhere to their treatment regimens.
Other potential methods, such as electronic drug monitoring
feedback [18] and theory-based intervention [19], are needed
to examine their effectiveness in improving medication adher-
ence for patients with RA.
Mechanisms proposed by a theory can help understand
medication adherence more generally. Theory-based pro-
grams are demonstrated to be more effective in promoting
behavior change compared with atheoretical campaigns
[20–23]. However, although theory-based interventions are
debated as necessary for the success of health programs
[24], theory is often overlooked in intervention design and
evaluation [25]. It is important that interventions using content
based on theory provide an evaluation of the proposed mech-
anisms by which they are purported to affect behavior change
[26]. The aim of the present study was to evaluate an inter-
vention designed based on the theoretical underpinnings of the
health action process approach (HAPA; for an overview of the
HAPA and how it is used to change behavior see [27–29]) to
improve adherence to medication regimens of patients with
RA.
More specifically, important components in the self-
regulatory phase of the HAPA (action planning, how individ-
uals make plans to perform their intended behavior; coping
planning, how individuals make plans to overcome possible
obstacles in undertaking their intended behavior; and self-
monitoring, how individuals monitor their intended behavior)
[27–29] have been found to be effective in improving healthy
behaviors (e.g., treatment adherence, eating fruits and vegeta-
bles, and sleep hygiene behaviors) among different popula-
tions [30–32]. For example, using action planning techniques,
individuals can initiate a detailed plan to ensure they adhere to
their medication regimen. Using coping planning techniques,
individuals can overcome potential obstacles that may thwart
their good intentions to adhere to their medication regimen.
Using self-monitoring techniques, individuals can maintain
medication adherence by regularly checking this behavior.
Methods
The study adopted a pre-registered randomized controlled trial
design: Iranian Registry of Clinical Trials (identifier umber:
IRCT20180108038271N1; https://www.irct.ir/trial/28920).
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The ethics committee at Qazvin University of Medical
Sciences (identification number: IR.QUMS.REC.1396.388)
approved the study. All participants provided written
informed consent prior to taking part in the study. More
specifically, a preliminary session was held to deliver the
study information. During the session, the first author was
responsible for answering potential questions from the
patients and consent forms were distributed for participants
to read and sign.
Participants and study design
The study adopted a single-blind randomized controlled
trial (RCT) of 6-month duration and was conducted at
two rheumatology outpatient clinics at two large univer-
sity teaching hospitals in the city of Qazvin, Iran, from
June 2018 to May 2019. Patients were eligible to par-
ticipate if they had a confirmed diagnosis of RA accord-
ing to the 2010 American College of Rheumatology
(ACR) /European League Aga ins t Rheuma t i sm
(EULAR) criteria, were aged 18 years and older, and
had the ability to understand written and spoken
Persian language. Participants were excluded if they
had a major psychiatric condition (e.g., schizophrenia,
mood disorders, and substance-related disorders), severe
kidney disease (this is because such patients need to
have frequent consultations about their medication re-
gime with their medical doctors which, in turn, might
influence their medication adherence behaviors), the in-
ability to take medication independently, and/or severe
cognitive impairment (i.e., self-reported diagnosis of de-
mentia and/or score < 24 on the Mini-Mental State
Examination).
A flow diagram of the random assignment of patients in the
study is presented in Fig. 1, and participant demographics are
presented in Table 1. Recruiting research assistants were
blinded to participant group allocation, and after baseline data
were collected, participants were randomized to study condi-
tions. The intervention contained three sessions, each spaced
1 week apart, and follow-up data were collected at 3 and
6 months post-intervention delivery. No additional tasks and
resources were provided to the participants between sessions.
Intervention sessions were conducted in a conference room in
the outpatient setting while participants waited to attend their
rheumatologist appointment. This waiting process usually
takes about 1.5 h; thus, all consenting patients were able to
participate in the sessions. As all patients needed to attend
routine rheumatologist appointments on a regular basis, all
three sessions were able to be completed. All participants
completed the primary and secondary measures three times:
baseline (before the intervention), 3 months after the interven-
tion, and 6 months after the intervention.
Randomization and blinding
At baseline, research assistants, who were registered nurses,
obtained signed written consent from each participant and
administered questionnaires assessing the study’s primary
and secondary outcomes (see sections of “Primary outcome
of change in medication adherence”, “Secondary outcome
measures of change in health outcome factors”, and
“Secondary outcomemeasures of theory-based self-regulation
factors” for details). Participants were then randomly assigned
into one of two groups: an intervention group or a treatment-
as-usual group. The randomization was conducted by a bio-
statistician at Tehran University of Medical Sciences who was
not part of the study and who used a computer-generated
block randomization (a combination block sizes of 2, 4, and
6) with 1:1 allocation between the intervention group and
treatment-as-usual group. Because of the nature of the inter-
vention, it was not possible to blind the participant to their
treatment allocation, although the research assistants who
helped in distributing the questionnaires and the biostatistician
who analyzed the data were blinded to patient allocation
groups. Moreover, the research assistants who assessed pri-
mary and secondary outcomes at baseline and follow-up as-
sessments were blinded to the allocation groups.
Intervention group
The present study adopted a theory-based intervention based
on the HAPA to improve the primary outcome of patients’
medication adherence [33–36]. The intervention comprised a
three-session training program based on behavior change
techniques (BCTs) that mapped onto key theoretical con-
structs of the HAPA [35]. Each session lasted approximately
40 min. All sessions were delivered by the first author, who
was trained in the delivery of theory-based interventions under
the supervision of the last author, an expert in the delivery of
health behavior change interventions in clinical settings. Both
group and individual sessions were used to improve patients’
attitude and motivation as well as increase medication adher-
ence behavior. The therapist (i.e., the first author) who deliv-
ered the training had received prior training in health
behavior promotion. Therefore, he used techniques to enhance
participants’ engagement, such as motivational interviewing.
However, the present study did not request the therapist to
utilize any specific techniques, except for BCTs, to help pro-
mote participants’ engagement. All sessions allowed for
some flexibility to tailor the content to fit participants’ needs,
including their health literacy level.
In sessions one and two, outcome expectancies and risk
perceptions were targeted. Specifically, in session one, pa-
tients’ beliefs regarding their medication taking (e.g., side-
effects, withdrawal symptoms, addiction, interactions be-
tween medicines) and their RA condition (e.g., risk factors,
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long-term complications) were elicited. During this session,
the facilitator corrected any misunderstanding by providing
factual evidence. The facilitator also highlighted the necessity
of adherence to medication regimens including addressing
Assessed for eligibility (n = 321)
Excluded (n = 121)
Did not meet inclusion criteria (n = 108): 
Drug or alcohol misuse disorders (n = 11)
MMSE < 24 (n = 27) 
Severe kidney disease (n = 6)
Not responsible for taking own medication (n =
37)
major psychiatric problems (n = 16)
Declined to participate (n = 24)
Lost contact (n=0)
Analysed (intention to treat) (n = 100)
Excluded from analysis (n = 0)
Lost to follow-up (n = 12)
Moved away (n = 4)
Allocated to treatment-as-usual (n = 100)
Received allocated intervention (n = 100)
Did not receive allocated intervention (n = 0)
Lost to follow-up (n = 16)
Moved away (n = 2)
Allocated to intervention (n = 100)
Received allocated intervention (n = 100)
Did not receive allocated intervention (n = 0)
Analysed (intention to treat) (n = 100)
Excluded from analysis (n = 0)
Allocation
Analysis
Follow-up
randomized 
(n = 200)
Enrollment
Fig. 1 Flow diagram for random assignment of patients in the study
Table 1 Baseline study sample
characteristics and descriptive
statistics for control variables
Treatment-as-usual (n = 100) Intervention (n = 100) p value
Age, years; mean ± SD 55.0 ± 15.4 52.4 ± 13.6 0.24
Years of education; mean ± SD 7.1 ± 3.2 7.0 ± 3.0 0.52
Body mass index, kg/m2; mean ± SD 26.5 ± 5.2 25.9 ± 4.6 0.20
Marital status; n (%) 0.15
Single 12 (12.0) 9 (9.0)
Married 67 (67.0) 58 (58.0)
Divorced/widowed 21 (21.0) 33 (33.0)
Sex; n (%) 0.66
Male 11 (11.0) 13 (13.0)
Female 89 (89.0) 87 (87.0)
Disease duration (years); mean ± SD 9.3 ± 6.5 8.9 ± 7.0 0.17
Anxiety; mean ± SD 8.2 ± 3.1 7.6 ± 3.2 0.15
Depression; mean ± SD 6.0 ± 2.2 6.1 ± 2.1 0.95
No. of DMARDs used; n (%)a 0.32
1 DMARD 10 (10.0) 8 (8.0)
2 DMARDs 78 (78.0) 81 (81.0)
3 ≥DMARDs 12 (12.0) 11 (11.0)
SD, standard deviation; DMARD, disease-modifying anti-rheumatic drugs
a Azathioprine, hydroxychloroquine, leflunomide, methotrexate, prednisone/prednisolone or sulfasalazine,
adalimumab, methylprednisolone, etanercept, methotrexate, abatacept, infliximab, or rituximab
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underpinning beliefs; for example, concerns about potential
adverse effects. The BCTs of information about health conse-
quences (BCT 5.1) and salience of consequences (BCT 5.2)
were used in this session. Building on session one, in session
two, patients were asked to list the potential benefits of taking
their medications and potential risks of not taking their med-
ications. Here, the facilitator encouraged the patients to reflect
on the positive and negative consequences of adhering to their
medication regimens, and helped address any ambivalence
and/or discrepancy in their beliefs. Moreover, and targeting
patients’ self-efficacy, role modeling of effective behavior
was provided through the use of testimonials, matched by
sex and age to the patient, of successful medication
adherence-related stories (BCT 16.3). Patients were then en-
couraged to focus on past successes (BCT 15.3) by either
remembering their own successful experiences of taking their
medications or by checking some example statements of
others’ medication adherence-related success stories. In the
final session, session three, planning and self-monitoring were
targeted. Here, patients were prompted to make concrete ac-
tion plans about when, where, and how they would take their
medications according to their medication regimen (BCT 1.4).
In addition, patients were encouraged to generate their own
coping plans (BCT 1.2). For this task, patients were required
to write down obstacles that may prevent them from taking
their medications according to their regimen and then identify
corresponding methods to overcome these obstacles. Finally,
a self-monitoring of behavior activity was provided (BCT
2.3). Here, patients were given a medication use calendar with
the suggestion to record their medication taking over a 1-
month period. Intervention content was not tailored to the
individual specifically; however, in the first session partici-
pants were able to discuss any issues they were currently hav-
ing with their condition and medication use and, thus, the
facilitator could correct any misunderstanding by providing
factual evidence.
Treatment-as-usual group
Patients in the treatment-as-usual control group received stan-
dard care. This included routine education counseling regard-
ing prescribed medications and general information
concerning RA delivered by a healthcare professional during
usual consultation visits.
Primary outcome of change in medication adherence
Medication Adherence Rating Scale The Medication
Adherence Rating Scale (MARS) is a self-report instrument
comprising five items assessing the performance of medica-
tion adherence. A five-point Likert-type scale was used [37],
where a higher score represents better medication adherence.
Previous research has shown good psychometric properties
for the measure [37]. Participants were instructed to consider
their RA medication adherence behaviors when they
responded to the MARS. Internal consistency of the scale
was satisfactory: α = 0.81 in the present study.
Secondary outcome measures of change in health
outcome factors
Health Assessment Questionnaire Disability Index The Health
Assessment Questionnaire Disability Index (HAQ) is a self-
report instrument, comprising 20 items concerning the func-
tional ability of RA patients [38]. A four-point Likert-type
scale was used, where a higher score represents worse func-
tional ability. Previous research has shown good psychometric
properties for the measure [38]. Internal consistency of the
scale was satisfactory: α = 0.89 in the present study.
12-Item Short Form Survey The 12-Item Short Form Survey
(SF-12) is a self-report instrument comprising 24 items. The
measure contains a summary assessment of quality of life in
two domains: a physical component summary (PCS) and a
mental component summary (MCS). The two domains com-
prise 12 items, which are rated on a variety of response scales,
including 2 to 6 categories (i.e., two-point to six-point Likert-
type scales). The domain scores are converted into a 0–100
scale, where a higher score indicates better quality of life.
Previous research has shown good psychometric properties
for the measure [39]. Internal consistency of the two domains
was satisfactory: α = 0.79 for PCS and 0.84 for MCS in the
present study.
Visual Analog Scale The VAS was measured using 1 item that
assessed self-reported perceptions of pain. A 0–100-mm scale
anchored by “no pain” (score of 0) and “the most extreme pain
possible” or “worst imaginable pain” (score of 100) was used
[40].
Secondary outcome measures of theory-based self-
regulation factors
The participants were instructed to consider their RA medica-
tion adherence behaviors when responding to the following
secondary outcome measures.
Beliefs about Medications Questionnaire–specific The Beliefs
about Medications Questionnaire-specific (BMQ–specific) is
a self-report instrument comprising 10 items. The measure
contains two domains of necessity (BMQ-necessity; sample
item “My health in the future will depend on mymedication”)
and concerns (BMQ-concerns; sample item “My medication
disrupts my life”). Each BMQ specific domain comprises five
items. A five-point Likert-type scale was used, where a higher
score on the BMQ-necessity represents more positive beliefs
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concerning medication and a higher score on the BMQ-
concerns represents more negative beliefs [41]. Previous re-
search has shown good psychometric properties for the mea-
sure [41, 42]. Internal consistency of the two domains was
very good to excellent: α = 0.88 for BMQ-necessity and
0.92 for BMQ-concerns in the present study.
Intention Intention to take medication was assessed using five
items (sample item “I intend to regularly take medicine in the
future”). A five-point Likert-type scale was used, where a
higher score represents stronger intention to take medication.
Previous research has shown good psychometric properties
for the measure [41]. Internal consistency of the scale was
excellent: α = 0.91 in the present study.
Self-efficacy Self-efficacy was assessed using four items relat-
ing to patients’ perceived control and confidence over taking
their medication (sample item “For me to take regular medi-
cation in the future is difficult/easy”). A five-point Likert-type
scale was used, where a higher score represents stronger self-
efficacy toward taking medication. Previous research has
shown good psychometric properties for the measure [41].
Internal consistency of the scale was very good: α = 0.89 in
the present study.
Action and coping planning Action and coping planning were
assessed using four items for each scale assessing the extent to
which patients’ planned to take their medication (action plan-
ning; sample item “I havemade a detailed plan regarding when
to take medication”) and planned to deal with setbacks (coping
planning; sample item “I have made a detailed plan regarding
what to take medication if I forgot it”). A five-point Likert-type
scale was used, where a higher score represents better action
planning to take medication. Previous research has shown
good psychometric properties for the measure [41]. Internal
consistency of the two scales was very good to excellent:
α = 0.90 for action planning and 0.86 for coping planning in
the present study.
Self-monitoring Self-monitoring was assessed using three
items related to patients’ self-monitoring concerning the tak-
ing of medication (sample item “During the last month, I have
consistently monitored when to take medications”). A five-
point Likert-type scale was used, where a higher score repre-
sents stronger self-monitoring behavior to take medication.
Previous research has shown good psychometric properties
for the measure [41]. Internal consistency of the scale was
very good: α = 0.88 in the present study.
Self-Report Behavioral Automaticity Index The Self-Report
Behavioral Automaticity Index (SRBAI) is a self-report in-
strument comprising four items that examine the extent to
which a particular behavior (e.g., taking medication) is
automatic for an individual [43]. A five-point Likert-type
scale was used, where a higher score of the SRBAI represents
more automatic action in takingmedication. Previous research
has shown good psychometric properties for the measure [41].
Internal consistency of the scale was very good: α = 0.87 in
the present study.
Control variables
Hospital Anxiety and Depression Scale The Hospital Anxiety
and Depression Scale (HADS) is a self-report instrument that
contains two domains of anxiety and depression to examine
psychological distress. The two domains comprise 14 items
which are rated on a four-point Likert-type scale. A higher
score of HADS represents a higher level of psychological
distress. The psychometric properties of the HADS are satis-
factory in its construct validity (i.e., unidimensionality of the
anxiety and depression subscale has been supported by the
Rasch analyses; the two-factor structure of the HADS has
been supported by the confirmatory factor analysis) [44].
Background Factors Body mass index (BMI) was calculated
using height and weight (i.e., kg/m2). Height and weight of the
participants were measured using standard tools by the re-
search associates who had received training in measuring an-
thropometrics. The number of disease-modifying anti-
rheumatic drugs (DMARDs) used, disease duration (i.e.,
how long a participant was diagnosed with RA), age (in
years), education (in years), marital status, and sex (female
coded as 0 and male as 1) were collected from the medical
records of the patients.
Sample size calculation
Sample size was calculated according to the primary outcome
measure (i.e., the MARS): that is, whether intervention effects
on medication adherence can be detected. The sample size
calculation was estimated using the following conditions: a
medium effect size (d = 0.5), power at 90%, and type I error
at 0.05 in a two-sided test. It was estimated that 86 patients
were needed per group. Utilizing a 15% attrition rate, it was
determined that the sample size of 100 per treatment was
needed.
Statistical analysis
Participant characteristics and baseline data are described
using means and standard deviations (SD) for continuous var-
iables and frequency and/or percentages (%) for categorical
variables. To evaluate the magnitude of changes in primary
(i.e., MARS) and secondary outcomes over time across the
two groups, linear mixed models (PROCMIXEDmacro) were
performed while controlling for age, sex, disease-modifying
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anti-rheumatic drugs used, body mass index, marital status,
years of education, depression, anxiety, and disease duration.
Summated scores were applied to all the instruments rather
than difference scores for the linear mixed-effects models.
Linear mixed models were conducted because they adopt ro-
bust algorism to estimate values for those who were lost to
follow-up and, therefore, fulfilling the principle of intention to
treat [45]. The distributions of all the variables were examined
using q-q plot and Kolmogrov-Smirnov test. Except for
MARS, all other variables had a normal distribution.
Therefore, for the analyses using MARS, a log-
transformation score on MARS which was normally distrib-
uted was applied. The linear mixedmodels, which handled the
missing values in the present study, were performed using
SAS version 9.3 (SAS Institute Inc., Cary, NC, USA). To
evaluate the effects of the proposed theory in improving med-
ication adherence, a mediation model was performed using
MARS assessed at the 6-month follow-up as the dependent
variable, treatment group (i.e., intervention vs. treatment-as-
usual) as the independent variables, and the following vari-
ables assessed at the 3-month follow-up as mediators: BMQ-
necessity, BMQ-concern, intention, self-efficacy, action plan-
ning, coping planning, self-monitoring, and SRBAI.
Moreover, the appropriateness of model was assessed by like-
lihood ratio test; the normality and homogeneity of variance
were checked using residual analysis. A random intercept
model was fitted to the data and the intercept was the only
variable that allowed to be varied. In addition, all the numer-
ical variables in the linear mixed-effects models were centered
to avoid multicollinearity. The mediation model was per-
formed using IBM SPSS 23.0 (IBM Corp., Armonk, NY)
with the PROCESSmacro (model 4). A bootstrappingmethod
with 10,000 resamples was used to estimate standard errors of
indirect effects. More specifically, bias-corrected
bootstrapped samples were used to calculate the 95% confi-
dence intervals. All p values were two-sided and were evalu-
ated as statistically significant at the 0.05 level.
Results
In order to check the fidelity of the intervention, 30% of the
audio-recorded transcripts of intervention sessions (n = 30)
were checked by the last author and an independent researcher
in terms of adherence to the study protocol. The fidelity of the
intervention was designed by the NIH Behavior Change
Consortium (NIH BCC) and included elements of study de-
sign, provider training, delivery of treatment, receipt of treat-
ment, and enactment of treatment. The last author and an
independent researcher coded all study materials (i.e., audio-
tapes and transcripts) into component BCTs using a recently
adapted taxonomy of BCTs [36]. Interrater reliability for each
of these transcripts was calculated and found to have a
Cohen’s κ of > 0.70 for each transcript, demonstrating good
interrater reliability of the coding process.
Table 1 presents participant demographic characteristics at
baseline, and Table 2 shows descriptive statistics for all out-
comemeasures, including information of internal consistency,
across time in the intervention group and the treatment-as-
usual group.
Further analyses using all the participants (i.e., n = 200)
showed that the improvements in the intervention group were
found to be significant in the linear mixed-effects models with
the restrictedmaximum likelihood estimation (see Table 3 and
Supplementary Tables S1 and S2). The overall interaction
effects between intervention and time were significant for all
outcome variables (p < 0.001). Therefore, the effects of inter-
vention (intervention group vs. treatment-as-usual group) at
different time points (3 months and 6 months vs. baseline)
were explored. More specifically, the intervention group re-
ported greater improvements compared with the treatment-as-
usual group in MARS score: coefficient = 3.89 (SE = 0.83;
p < 0.001) at 3-month follow-up; coefficient = 4.50 (SE =
0.80; p < 0.001) at 6-month follow-up. The intervention group
also reported greater improvements compared with the
treatment-as-usual group in all the health outcome measures
(Supplementary Tables S1 and S2) and proposed theory-based
self-regulation variables (Supplementary Tables S3 to S6).
Furthermore, intervention effects on medication adherence
scores were found to be mediated by some of the theory-based
self-regulatory variables that guided the study (see Table 4). In
Table 4, the total effect (i.e., the sum of direct and indirect
effects) of the intervention on MARS was found to be mainly
contributed by indirect effects (coefficient = 4.49; 95% CI =
2.91, 6.23). Moreover, the direct effect of intervention on
MARS was not significant (coefficient = 0.34; SE = 1.12;
p = 0.76). After separating the total indirect effect, all the me-
diators except self-efficacy and action planning showed a sig-
nificant indirect effect.
Discussion
The results of the present study showed that the intervention
significantly improved patients’ medication adherence scores.
Specifically, RA patients in the intervention group had nearly
perfect adherence scores (24.55 out of 25) at 6 months, as well
as produced more positive health outcomes and social cogni-
tions. Moreover, the mediation effect of the theory-based self-
regulation factors onmedication adherencewas assessedwhere it
was found that medication beliefs, intention, coping planning,
self-monitoring, and behavioral automaticity were significant
mediators of the intervention effect on medication adherence
scores. A number of studies [13–16] have designed different
treatments aimed at improving medication adherence for RA
patients. However, studies have rarely examined the process in
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the theory-proposed mechanisms to explain treatment effects.
Thus, the present study extends current understandings of the
key determinants in this context.
The current intervention included behavior change strategies
that targeted both motivational (e.g., outcome expectancies) and
volitional (e.g., planning, self-monitoring) components to im-
prove behavior. This is consistent with other health programs
[46–48]. The HAPAmakes the distinction between motivational
and volitional phases involved in the change process, where
constructs like outcome expectancies and risk perceptions help
to form an intention in the motivational phase; self-efficacy,
planning, and self-monitoring help to enact intentions in the vo-
litional phase; and intention is the bridge between the motiva-
tional and volitional phases [26–29]. Based on this, intervention
design needs to target the appropriate components within each
phase that are most likely to move the individual further toward
goal attainment. GivenRApatientsmay not be fullymotivated to
adhere to their medication regimen, the current intervention first
targeted strategies to promote intention formation and then
moved to using strategies that focused on helping the patients
to enact their intentions. The findings of the mediation effect of
the theory-based self-regulation factors on medication adherence
supported adopting this approach.
Further, it has been demonstrated that interventions that
incorporate more behavior change techniques have larger
effects compared with interventions that incorporate fewer
techniques [25]. Thus, in the context of this study, it seems
that the use of multiple techniques including getting pa-
tients to explore their beliefs about taking their medica-
tions and getting them to plan and monitor their perfor-
mance is useful. The latter strategies of planning and mon-
itoring may be especially important given they are shown
to help in building habits [26] and, thus, more automatic
performance of the behavior, and that findings of the pres-
ent study showed intervention effects to be mediated by
behavioral automaticity.
Table 2 Descriptive statistics for all outcome measures across time in the intervention (INT) and the treatment-as-usual (TAU) groups
Variable (score range) Group Mean (SD)
N = 100 at baseline N at month 3 N at month 6 Baseline Month 3 Month 6
Medication Adherence Rating Scale (5–25) TAU 93 88 19.9 (8.0) 19.6 (6.9) 19.7 (6.7)
INT 91 89 19.6 (5.5) 23.8 (5.9) 24.6 (6.0)
HAQ (0–3) TAU 92 85 0.6 (0.3) 0.6 (0.5) 0.5 (0.4)
INT 88 86 0.6 (0.4) 0.3 (0.1) 0.2 (0.2)
Short Form-12: PCS (0–100) TAU 91 89 50.8 (31.8) 50.3 (32.0) 50.0 (32.3)
INT 89 87 53.4 (34.1) 58.0 (31.0) 61.2 (29.1)
Short Form-12: MCS (0–100) TAU 93 89 51.9 (28.3) 52.4 (28.5) 52.7 (28.8)
INT 87 85 55.5 (28.8) 64.9 (25.6) 66.7 (24.1)
Visual analog scale on pain (0–100) TAU 94 86 42.0 (32.4) 42.3 (31.9) 43.5 (31.8)
INT 90 81 40.5 (32.4) 30.8 (29.3) 31.4 (20.4)
BMQ-necessity (5–25) TAU 89 88 13.9 (4.5) 14.1 (4.5) 14.5 (4.7)
INT 90 90 13.9 (4.4) 17.1 (4.5) 17.3 (4.9)
BMQ-concerns (5–25) TAU 91 89 16.4 (3.8) 15.7 (4.4) 15.2 (4.3)
INT 88 83 16.7 (3.6) 10.5 (3.3) 10.0 (5.1)
Intention (1–5) TAU 95 85 3.1 (1.9) 3.0 (2.0) 2.9 (1.9)
INT 91 86 3.1 (1.8) 3.5 (2.0) 3.5 (2.1)
Self-efficacy (1–5) TAU 97 87 2.3 (1.9) 2.3 (1.0) 2.3 (1.1)
INT 94 85 2.3 (1.2) 3.6 (1.4) 3.8 (1.4)
Action planning (1–5) TAU 93 88 2.4 (2.0) 2.2 (1.3) 2.1 (1.2)
INT 91 90 2.4 (1.3) 4.5 (1.9) 4.8 (2.6)
Self-monitoring (1–5) TAU 93 90 2.6 (1.1) 2.5 (1.2) 2.5 (1.3)
INT 96 84 2.7 (1.2) 4.3 (1.9) 4.7 (2.7)
Coping planning (1–5) TAU 92 82 2.4 (2.0) 2.3 (1.2) 2.4 (1.1)
INT 94 90 2.4 (1.3) 4.3 (1.9) 4.7 (1.5)
Self-Report Behavioral Automaticity Index (1–5) TAU 95 91 2.8 (1.1) 2.7 (1.3) 2.7 (1.0)
INT 93 89 2.8 (1.1) 3.2 (1.1) 3.2 (1.3)
Internal consistency presented using Cronbach’s α.HAQ, Health Assessment Questionnaire Disability Index score; PCS, physical component summary;
MCS, mental component summary; BMQ, Beliefs about Medications Questionnaire–specific
Clin Rheumatol
Given these findings, it is likely that self-regulation factors are
important contributors to RA patients’medication adherence and
related health outcomes. The intervention effects found in our
study are in line with prior research findings. That is, beliefs
about medications are key factors for RA patients to improve
their medication adherence [16]. Subsequently, the improved
medication adherence may further elevate the health, such as
quality of life, for RA patients [7–9].
Limitations and conclusion
Despite the promising results of the intervention, findings of the
present study should be interpreted in light of its limitations.
Participants were recruited from Qazvin City; thus, findings
may not be representative of those living in more rural areas
and to other ethnic groups. Another limitation that should be
noted is the use of self-report measures formedication adherence,
which may be prone to memory or social desirability bias. As an
alternative to self-report, objective instruments could be used,
such as medication possession rate, electronic drug monitor, or
serum concentration of medication on medication adherence.
However, it should be noted that previous research has shown
significant associations betweenMARS and objectively assessed
medication adherence [37]. Nevertheless, the lack of objective
measures of disease activity and laboratory work in the present
study is an important limitation. Further, placebo effects cannot
be ruled out given participant blinding was not possible.
Moreover, physical and laboratory data (e.g., Disease Activity
Score, blood markers of ESR and CRP) were not collected in the
present study. Therefore, it is unclear whether intervention effects
could affect these physical aspects, especially the disease activity
Table 4 Models of the effect of the intervention onmedication adherence behavior with mediators of socio-cognitive variables controlling for age, sex,
disease-modifying anti-rheumatic drugs used, body mass index, marital status, years of education, depression, anxiety, and disease duration
Coefficient SE t p
Total effect of the intervention on MARS at 6 months 4.83 0.84 5.78 <0.001
Direct effect of intervention on MARS at 6 months 0.34 1.12 0.30 0.76
Indirect effect of intervention on MARS at 6 months Coefficient Boot SE Boot LLCI Boot ULCI
Total indirect effect of intervention on MARS at 6 months 4.49 0.84 2.91 6.23
Indirect effect of intervention for each individual mediator Coefficient Boot SE Boot LLCI Boot ULCI
BMQ-necessity at 3 months 0.19 17 0.13 0.57
BMQ-concerns at 3 months − 0.76 0.38 − 1.60 − 0.10
Intention at 3 months 1.45 0.51 0.55 2.52
Self-efficacy at 3 months 0.49 0.52 − 0.57 1.52
Action planning at 3 months 1.22 0.69 − 0.03 2.66
Coping planning at 3 months 1.18 0.57 0.05 2.74
Self-monitoring at 3 months 1.42 0.56 0.42 2.64
SRBAI at 3 months 1.70 0.44 0.90 2.62
MARS, Medication Adherence Rating Scale; BMQ, Beliefs about Medications Questionnaire–specific; SRBAI, Self-Report Behavioral Automaticity
Index; SE, standard error
Total effect of the intervention on MARS includes both direct and indirect effects of intervention on MARS. Indirect effect of intervention on MARS
includes each mediator’s indirect effect; therefore, a total indirect effect can be computed by summing up all the mediators’ indirect effects
Table 3 Linear mixed-effects models that predicted medication adher-
ence, controlling for age, sex, disease-modifying anti-rheumatic drugs
used, body mass index, marital status, years of education, depression,
anxiety, and disease duration
Variable MARS
Β 95% CI
Group (Ref: TAU) 0.32 − 1.31, 1.95
Time (Ref: baseline)
3 months 0.01 − 1.15, 1.17
6 months 0.24 − 0.94, 1.42
Group × time
INT vs. TAU at 3 months 3.89* 2.26, 5.52
INT vs. TAU at 6 months 4.50* 2.93, 6.07
Age − 0.02 − 0.06, 0.02
Sex (Ref: female) 0.12 − 1.86, 2.10
DMARDs used 0.12 − 0.06, 0.30
Body mass index − 0.18 − 0.40, 0.04
Marital status (Ref: single) 0.06 − 0.18, 0.30
Years of education 0.02 − 0.12, 0.16
Depression − 0.08 − 0.14, − 0.02
Anxiety − 0.05 − 0.11, 0.01
Disease duration 0.03 − 0.15, 0.21
Ref., reference group for comparison; TAU, treatment as usual group;
INT, intervention group; MARS, Medication Adherence Rating Scale.
*p values < 0.001
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which is a significant confounder in the present study. Following
this, a longer period of time for follow-up assessments is sug-
gested to investigate long-term maintenance effects of the
intervention.
This theory-based intervention resulted in an improvement
in medication adherence behavior and improved health out-
comes and social cognitions, and this was evident both in the
short and long term. In addition, the present study attempted to
further elucidate the mechanisms of changing medication ad-
herence behaviors in a clinical sample of patients at risk for
nonadherence behaviors. Overall, the results of the present
study support the use of a theory-based intervention for im-
proving medication adherence among RA patients and make a
contribution to the cumulative knowledge about self-
regulatory processes in health behavior change.
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